A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839

Trial Profile

A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Vatelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Sanofi Genzyme
  • Most Recent Events

    • 12 Jul 2016 Status changed from active, no longer recruiting to discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.
    • 02 May 2016 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
    • 02 May 2016 Time frame for primary end points has been modified .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top